HANSARD
SITTING CALENDAR
SEARCH
LIVE BROADCAST
Hansard Dynamic Subject Index
House of Assembly - Fifty-Fifth Parliament, First Session (55-1)
2023-02-08 Daily Xml
Contents
Xml

Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill

Second Reading

Adjourned debate on second reading.

(Continued from 7 September 2022.)

Mrs HURN (Schubert) (16:46): I rise to indicate that I am the lead speaker for the opposition and indicate support for this bill. The former Liberal government actually introduced an identical bill in the other place, which was introduced into this house in 2021. This bill will allow the South Australian Gene Technology Act 2001 to adopt future amendments to the commonwealth gene technology legislation by regulation. The objective of the commonwealth Gene Technology Act is, and I quote:

…to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with GMOs.

There is an independent statutory officer, known as the Gene Technology Regulator, who is responsible for administering this objective. Really, what we are trying to avoid right across the nation are periods where state legislation is inconsistent and out of step with the National Gene Technology Scheme. That is the very purpose of this legislation. The purpose of this bill particularly is ensuring that South Australia remains in step with the commonwealth and that there are not any lag times, periods of legislative lag.

Naturally, every state and territory administers the National Gene Technology Scheme through their respective laws, mirroring the commonwealth gene legislation. However, every jurisdiction takes a very different approach to adopting this commonwealth legislation. Currently, in South Australia there is a full parliamentary and legislative process each time there are amendments to commonwealth law. Due to the nature of this process, this of course can lead to inconsistencies with regulatory requirements while this process is being undertaken.

Should this bill be successful through both houses, which I imagine that it will be, it would mean that changes to the commonwealth legislation would be considered by the South Australian government as an amendment of the act regulations, with options to adopt, not adopt or adopt with modification any changes to the commonwealth gene technology laws. Naturally, the parliament would retain the right to review and disallow these regulations, so the oversight still remains, which I think is really important, but simply in a more streamlined way.

I would like to point out as well that changes can only be made to the commonwealth legislation after consideration by the Gene Technology Forum of which the Minister for Health and Wellbeing is a South Australian member and with full consultation as well, which I think is vital.

The opposition supports the bill because, as we have been advised, this will ensure that our regulatory requirements are consistent. It will certainly reduce confusion and it will really minimise the risk of noncompliance for clinicians, reduce the risk for researchers, for industry, for transport companies and all those who deal with gene technology.

Ms THOMPSON (Davenport) (16:50): I rise to offer my support for the Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill presently before the house. This legislation aims to improve consistency between commonwealth and state legislation.

Changes to the commonwealth Gene Technology Act and subordinate legislation is amended on a regular basis, which can lead to misalignment to state legislation and cause unnecessary confusion to operators across jurisdictions.

The bill allows our state to adopt changes to commonwealth law by regulation rather than undergoing a full legislative process each time a change is made at a commonwealth level. A similar bill was introduced by the former government and received support from the now government. The model adopted in this bill is the same as that approved by the previous minister for health and wellbeing. We look forward to working constructively as this bill is progressed.

Gene technology is the term given to a range of activities concerned with understanding gene expression, taking advantage of natural genetic variation, modifying genes and transferring genes to new hosts. It is used in South Australia for a broad range of applications, primarily by our university sector and other researchers for very important work. It is used in agriculture, for example, for the development of crops that are genetically adapted to better cope with the environmental stresses caused by climate change. It can even be used as a control measure to alter the fertility of pests.

The South Australian Research and Development Institute manages the Australian Pastures Genebank which provides a databank of genetic material for more than 70,000 plants. The Department of Primary Industries supports a number of agtech developments, including the use of gene technology to enable more efficient primary production practices in our state. Importantly, gene technology is used with clinical trials and the development of medicines, including vaccines, or for the study of diseases.

A local example of this is the ongoing important research being undertaken by the South Australian Health and Medical Research Institute and SA Pathology into blood cancers, including the genetic inheritance of these conditions. This type of research is so important to so many of us who have had our own health problems or who have family members suffering from diseases that would benefit from clinical trials and new medicines.

As the government's parliamentary co-convenor for Dementia Australia, I was particularly pleased to learn that a recent gene therapy trial for Alzheimer's disease produced beneficial effects in slowing progression of the disease by approximately 50 per cent. This trial saw genetically modified cells injected directly into the brains of test subjects, which helped to improve cell growth and repair. While this trial was small, such research is vital to the improvement of outcomes and survival of patients. Although the study is very preliminary, it indicates that gene therapy may provide beneficial treatment for Alzheimer's disease in the future, which is extremely exciting.

The alignment of the South Australian and federal gene therapy legislation will reduce confusion for researchers and others who undertake gene technology processes, such as these described, by ensuring that regulatory requirements are clear and transparent.

Health and medical research remains a priority of the Malinauskas Labor government because we know that innovation leads to better patient outcomes. That is why we have begun consultation on South Australia's first ever Health and Medical Research Strategy. Our government has commenced consultation with key industry stakeholders to ensure their research helps more South Australians.

Universities, including Flinders University, which is located in my electorate of Davenport, are one of these key stakeholders. They are doing groundbreaking work right here in South Australia. Just last week, I had the pleasure of touring the Flinders Motor Neurone Disease and Neurotrophic Research Lab where Associate Professor Mary-Louise Rogers and her incredible research team are working on non-invasive biomarkers for MND that can be used to determine if treatments are working in clinical trials or not. They are also asking fundamental questions about how MND starts, and have been looking at whether or not the MND gene that is present in about 10 per cent of MND cases can be altered or removed to prevent or treat the disease.

The Health and Medical Research Strategy will consider all aspects of the sector to improve health, social and economic outcomes for our community. The strategy will outline what is needed to minimise the time taken for groundbreaking research to translate into better health outcomes, including how innovative technology, such as gene technology, can boost productivity and performance.

I look forward to supporting medical research in South Australia to assist in improving health outcomes for all South Australians. We need to ensure that our gene technology legislation is as up to date as possible, so that we can continue our state's good work in this space.

The current process—which involves reviewing new commonwealth changes, developing a draft bill to amend the SA Gene Technology Act, and then passing it through two houses of parliament—is lengthy and inefficient. With this bill, parliament will still retain the right to review and disallow regulations. Objectionable amendments can be disallowed and allow the parliament to have scrutiny. Changes to the commonwealth legislation can only be made through the gene technology forum, at which our state's Minister for Health and Wellbeing is a representative, and following full public consultation.

Improving consistency of gene technology legislation between commonwealth and state is already in place in other jurisdictions, including Tasmania, the Northern Territory and Queensland, where their legislation allows them to apply the commonwealth laws with the ability to modify through regulations. The commonwealth government are likely to change their legislation in the near future. Adopting this bill will help ensure that our legislation is not out of date, and enable more important research and innovation here in South Australia. I commend this bill to the house.

Mrs PEARCE (King) (16:56): I rise to speak in support of the gene technology amendment bill, which seeks to improve the consistency between commonwealth and state legislation. Gene technology is a process that can see faulty genes replaced with healthy genes, turning off faulty genes that may be the cause of a disease or condition, or even adding a new gene in to treat a disease or systems of a condition. Gene technology can be used in clinical trials and the development of medicines, and it is technology that has made enormous positive developments in the biomedical field. In some settings, it has aided medical practitioners to diagnose genetic diseases and cancers more quickly and pinpoint therapies to address these diseases more quickly and more cheaply.

Interestingly, one of the first licensed drugs produced using gene technology was human insulin in 1982. The use of gene technology to produce insulin has made an enormous positive impact on the lives of millions of people worldwide. This development has now led to a huge improvement in the quality of life for people with diabetes, who can now effectively manage their blood sugar levels to live better, healthier lives.

In South Australia, gene technology is also used for a wide range of applications, particularly by our universities and researchers. For example, in 2018 Adelaide University conducted medical research into mitochondrial disease, where pigs were genetically modified to have extra copies of mitochondrial DNA in their reproductive cells. The South Australian Research and Development Institute manages the Australian Pastures Genebank, which provides a databank of genetic material for more than 70,000 plants. Ongoing research is also performed by the South Australian Health and Medical Research Institute and SA Pathology into blood cancers, including the genetic inheritance of these conditions. It can even be used in settings such as agriculture, aquaculture and livestock, and as a control measure to alter the fertility of pests and even study diseases.

The Department of Primary Industries and Regions SA supports a number of agtech developments that include the use of gene technology to enable more efficient primary production practices in SA. Last year, the University of Adelaide released their findings into the use of gene technology to control invasive mice. Through use of technology known as t-CRISPR, computer modelling was used on laboratory mice to make alterations to the female fertility gene. This would then render female mice infertile, in turn reducing the overall population.

This technology can be used as another tool in the arsenal of our agricultural sector, one that is far more humane and reduces the need to bait, which can be harmful to native species and, let us not forget, expensive. The potential of this research, done by our own University of Adelaide using gene technology, highlights the potential for the development of innovative solutions to what are big challenges that we need to overcome—and we need to be thinking big if we want to overcome some of the incredible challenges that face us this century.

Earlier last year I was lucky to attend the South Australian Young Tall Poppy Awards ceremony, which recognises Australian intellectual and scientific excellence and also encourages young Australians to follow in the footsteps of our outstanding achievers, to get excited about STEM and interested in using it to help solve some of our most complex problems. I mention this because I was utterly blown away by the 2022 South Australian Young Tall Poppy Science Award winner, the University of Adelaide's Dr Tatiana Soares da Costa.

Dr Soares da Costa is one of the many bright South Australians who are using gene technology to revolutionise the way we use herbicides to protect our vital agricultural industry. With more than 40 per cent of cropping land having been invaded by herbicide-resistant weeds, Dr Soares da Costas' work in developing a new multi-target herbicide will make it more difficult for weeds to evolve resistance and will prolong the efficacy of existing herbicides.

By understanding the structure, functions and regulations of essential proteins in bacteria and plants, Dr Soares da Costa is helping to solve one of the biggest challenges we face when it comes to resistance to herbicides and antibiotics, with the development of new classes of antibacterial and herbicide agents. Her innovative research is helping to combat challenges faced by society and ultimately to improve people's lives, as well helping to address weeds that outcompete crops for resources such as sunlight and nutrients, leading to reduced crop quality and yield. Her strategies to expedite bringing herbicides to the market will help support food security for future generations.

When it comes to gene technology as it currently stands, each time there is a change made at the commonwealth level, we undertake a full legislative process which can often be lengthy and inefficient. This means we must review the commonwealth changes, a bill is drafted to amend the Gene Technology Act, and then it must make its way through both this place and the other place. This can mean it often takes six to seven months, in total, to update state legislation to reflect the changes that have been made by the commonwealth government.

Currently, changes to the commonwealth Gene Technology Act and subordinate legislation can be misaligned to that of state legislation, causing unnecessary confusion to operators across jurisdictions. Around Australia, Tasmania, the Northern Territory and Queensland apply commonwealth laws, with the ability to modify them through regulations, and New South Wales applies the laws directly. Victoria and the ACT both go through the usual parliamentary process.

This bill allows for changes in commonwealth legislation to be adopted by regulation, while still allowing the parliament to retain the right to review or disallow regulations, with objectionable amendments able to be disallowed while—very importantly—still allowing parliament to have scrutiny.

The model adopted in this bill is the same as that approved by the previous Minister for Health and Wellbeing and, with a similar bill introduced late in 2021 that had the support of the then Labor opposition, we are seeking to ensure that our legislation is not out of date with that of the commonwealth, making the process more efficient. Public consultation was undertaken on the Gene Technology Bill over six weeks, with a consultation paper and the use of a survey via the YourSAy website under the former government.

Support is there within our community for gene technology and, as a state, we are in many ways at the forefront of gene technology developments. These developments will benefit the way we provide medical treatments, in turn improving the health of the population, increasing food security by arming our agricultural sector with the means to increase productivity, and benefiting our environment by reducing reliance on harmful pesticides.

What excites me greatly about technology such as gene technology is that it has the ability to think outside the box to tackle the big issues: challenges that will need not only the brightest minds we have now but those minds that we will require in the future. I am sure it is also exciting for the next generation of scientists—young future scientists who may not even know it yet but may be looking up to leaders in this space like Dr Soares da Costa and thinking to themselves that they can do it as well.

With each new development, whether they be environmental benefits of tackling herbicide resistant weeds, tackling invasive species with out-of-the-box thinking or improving the potential health outcomes of our loved ones, groundbreaking technology like this has the opportunity to inspire. I know I walked away from learning about Dr Soares da Costa feeling inspired. By making it more efficient, we can provide some greater clarity for our brilliant researchers in this space, such as continuing developing groundbreaking research to help us tackle some of the biggest challenges we will face this century. With that, I commend the bill to the house.

Ms CLANCY (Elder) (17:05): I rise today in support of the Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill. The crux of this bill is to improve consistency between commonwealth and state legislation. At the moment, whenever a change is made in the gene technology space on a federal level, we need to undertake a full legislative process in our state parliament, and that can take some time. Not only is this process lengthy but it is also quite inefficient. It can take months for a review of the commonwealth changes, a drafting of the bill to amend the SA Gene Technology Act and then to pass through both houses of our parliament.

The bill we are discussing today means that, instead of going through this extensive process, the changes can instead be made by regulation. That does not mean it will be a simple tick and flick without any review. It is really important to know that under this change parliament will still retain the right to review and disallow regulations. Objectionable amendments can be disallowed, which allows the parliament to have scrutiny. Also, changes to the commonwealth legislation are only currently able to be made through the gene technology forum and following full public consultation. Our Minister for Health, Minister Picton, is South Australia's representative on the forum.

Changes to the commonwealth Gene Technology Act and subordinate legislation are now not uncommon. These pieces of legislation are amended on a regular basis, which can lead to misalignment to state legislation and cause unnecessary confusion to operators across jurisdictions, hence the requirement for this bill. A similar bill was introduced by the former government and was supported by Labor but did not progress. In fact, the model adopted in this bill is the same as the one approved by the previous Minister for Health and Wellbeing, so we look forward to working constructively with those opposite for it to progress through both houses.

In South Australia, gene technology is used for a broad range of applications, primarily by our university sector and other researchers. The following are a few examples of work happening here in SA:

in 2018, Adelaide University conducted medical research into mitochondrial disease, where pigs were genetically modified to have extra copies of mitochondrial DNA in their reproductive cells;

the South Australian Research and Development Institute (SARDI) manages the Australian Pastures Genebank, which provides a databank of genetic material for more than 70,000 plants;

ongoing research by the South Australian Health and Medical Research Institute and SA Pathology into blood cancers, including the genetic inheritance of these conditions; and

the Department of Primary Industries and Regions SA (PIRSA) supports a number of agtech developments, including the use of gene technology, to enable more efficient primary production practices in SA.

Gene technology can be used:

in agriculture, aquaculture and livestock (for example, in the development of crops that are genetically adapted to meet environmental stresses caused by climate change);

in the study of diseases; and

as a control measure to alter the fertility of pests.

The commonwealth government is likely to change their legislation in the near future, so adopting this bill will help ensure that our legislation is not out of date and makes the process more efficient.

The previous health minister's bill was introduced late in the last parliamentary sitting; however, support was indicated by the then Labor opposition. Tasmania, Northern Territory and Queensland already apply the commonwealth laws with the ability to modify through regulation, so this is not a novel idea but one that will make a semi-regular occurrence more efficient. I commend the bill to the house.

Ms HOOD (Adelaide) (17:09): I rise to speak on the Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill. Genes are found in all living organisms and are inherited from one generation to the next, with gene technology being a process that makes changes to genes and allows for direct modifications to be made to the genetic construct of an organism. It is interesting to note that gene technology may be used in clinical trials and the development of medicines, including vaccines. It may be used in agriculture, aquaculture, livestock, the study of diseases and as a control measure to alter the fertility of pests.

In South Australia, gene technology is used in our state for a broad range of applications, primarily by our university sector and other researchers. As an example, in my electorate of Adelaide in 2018 the University of Adelaide conducted medical research into mitochondrial disease. As we heard, it is where pigs were genetically modified to have extra copies of mitochondrial DNA put into their reproductive cells.

In regard to this bill, as we have also heard, I understand that it is a similar bill to that introduced by the former government and received support from the now government and for that reason we look forward to working on both sides of the chamber to see this bill debated and passed.

This legislation aims to improve the consistency between commonwealth and state legislation, and it will allow for changes in commonwealth legislation to be adopted by regulation. It is very important to note that the regulation process still allows the government to review the proposed changes and decide if they are appropriate for the South Australian community.

But when we look at the current system, that is where we understand that there is a need for change. Currently, we have to undertake a full legislative process each time a change is made on the commonwealth level, which makes the current process quite lengthy and inefficient. As an example, it can take between six to seven months to review commonwealth changes and develop a draft bill to amend the SA Gene Technology Act and then gain approval via both houses of parliament.

A change to the commonwealth legislation is only currently able to be made through a gene technology forum following full public consultation, with our Minister for Heath, the member for Kaurna, being South Australia's representative on the forum. Because the commonwealth Gene Technology Act and subordinate legislation are amended on a regular basis, it can lead to misalignment between state legislation and cause unnecessary confusion to operators across jurisdictions. Adopting this bill will help ensure that our legislation is not out of date, and it will make the process much more efficient and consistent. With those comments, I commend the bill to the house.

The Hon. Z.L. BETTISON (Ramsay—Minister for Tourism, Minister for Multicultural Affairs) (17:12): I rise in support of the Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill 2022. The National Gene Technology Scheme is a collaboration between all Australian governments, supporting a nationally consistent regulatory system for gene technology in Australia. Currently, the National Gene Technology Scheme is administered by each state and territory via their respective laws. Each jurisdiction has an individual approach to how they adopt changes to the commonwealth legislation.

Currently, there are three separate approaches to the application of these laws across jurisdictions. Like many people in this house, we share an interest in efficiency and we share an interest in how we might be more consistent if we are to encourage investment in different areas. Certainly, the area of gene technology is incredibly exciting, and it has so many applications as well. If we are able to increase consistency, we will see that investment, whether from overseas or in South Australia or nationally, and they will see that they can take this opportunity to set up in any jurisdiction.

What that means is that we know we are a low-cost economy. We know that it is easier to set up a business here in South Australia. The Minister for Small Business is doing incredible work to address some of the concerns of business and making a one-stop shop. I think that this is really important in the theme that we are open for business. You heard from the Treasurer today how well our economy is going, and we have seen many people, particularly during recent events, remind themselves of why people love living in South Australia. It is a great place to raise your children, a very livable city, and we know from a tourism point of view that it is pretty exciting. A lot is happening here.

We already have in our DNA festivals as a key part of our culture, but now we are seen as a great place to hold events and the city really comes to life during those events. So we are attracting people here and I am keen, I am aspirational, to attract more head offices here from a tourism point of view. The key thing for me is not only to talk about the ecosystem of tourism head offices that are already here but the opportunities including a better quality of life for staff and lower costs to run businesses here. Gene technology is one of those areas of potential growth and one of those areas that we aspire to continue to be part of.

Currently, there are three separate approaches to the applications of these laws across jurisdictions. New South Wales applies the commonwealth legislation automatically whereas Tasmania, the Northern Territory and Queensland apply the commonwealth legislation automatically but with the ability to modify the legislation by regulation. That is the model that we are proposing here. Victoria and the ACT amend their state-based legislative schemes to align with the commonwealth amendments via the usual parliamentary process, which is similar to our current model in South Australia.

This bill before us aims to enable the adoption of amendments to the commonwealth gene technology laws via regulation as opposed to South Australia taking a full legislative process each time there are amendments to national laws. We think legislative process is incredibly important and that is what we are here to do. We are legislators, elected to this house to represent a geographical region in South Australia, but sometimes that legislative process can take time. Obviously one of the opportunities we have here is to look for those efficiencies where we can connect up, where we see other states already using this model that can become more efficient. I would say that, of course, we aim for efficiency and we prioritise what is most important in this house but often it does take time.

The commonwealth Gene Technology Act and subordinate legislation are amended on a regular basis, which can lead to misalignment with state legislation, causing unnecessary confusion across jurisdictions. SA Health has estimated to us that the current process is lengthy and can take up to seven months from reviewing the changes, drafting amendments to legislation and proceeding through both houses of parliament. This is neither a productive nor efficient way to adopt regular amendments, nor is it a good use of the parliament's time and resources. Under the proposed changes, objectionable amendments by the commonwealth could still be disallowed and this provides an avenue for parliamentary scrutiny.

Being a former member of the Legislative Review Committee, which often looks at subordinate legislation, I can tell you it is an incredibly thorough process and I encourage all members to spend some time on that committee. It is not all about cats, although that was frequently raised last time. It is an incredibly important committee that is across both houses of parliament that enables that scrutiny and enables disallowance motions to go ahead in either house, so that is something we have to back us up.

While we might be looking to be more productive and more efficient, we must never ever not be connected to what is happening and not give ourselves the opportunity to address concerns that have not been adequately covered previously.

A similar bill was introduced by the former government and received support from the now government. The model adopted in this bill is the same as that approved by the previous Minister for Health and Wellbeing, the Hon. Stephen Wade, in the other place, who has recently announced his retirement. We wish him all the very best in his retirement. No doubt, at times, it has been very challenging to be the health minister and of course at no other time than during COVID-19. Decisions had to be made, and health became the number one focus, and keeping us healthy and protecting us. I wish the Hon. Stephen Wade all the very best in his retirement.

Gene tech is used in South Australia for a broad range of applications, primarily by our university sector and other researchers. Examples of the work in SA are medical research into mitochondrial disease; medical research into blood cancers, including the genetic inheritance of these conditions; agtech development to enable more efficient primary production practices in South Australia; the development of medicines and vaccines; and a control measure to alter the fertility of pests. Gene technology work has incredibly wide applications across many issues. Of course, we are learning more and more each day, when I think about the research into blood cancers and the work that we have here.

Obviously, SAHMRI 2 is going up, the proton therapy unit, which I think is the only one in the Southern Hemisphere, as I recall. We know that the medical research that we have enables us to support not just South Australians but other Australians with these terrible conditions and enables us to keep going. South Australia's global leadership in medical technology is supported by our health science precinct, one of the largest in the Southern Hemisphere.

We are also a leading agricultural region with clean, green food and beverages, producing premium quality food and wine for global exports. I encourage people who have not yet had the chance to go to the Waite Campus of Adelaide University; they are doing world-class research there. When I was speaking to them, we were talking about our exports in barley and the opportunity for students around the world, international students, to come to South Australia to study at Waite as experts in their field. It is an incredibly important part of what we offer, particularly for postgraduate qualifications.

The sectors that I have talked about are being identified as key areas of growth for our state, and keeping legislation current and concurrent with the commonwealth position can only be of benefit to the work undertaken by our researchers.

We recently achieved record trade figures, with overseas goods exports reaching almost $15 billion in the last financial year, a 15 per cent increase on the previous year. Through the government's renewed approach to growing our share of the national exports, we can expect this to continue to grow over time.

Enabling our researchers to stay up to date with commonwealth amendments around gene technology will be a significant improvement. I commend the bill to the house.

The Hon. C.J. PICTON (Kaurna—Minister for Health and Wellbeing) (17:22): I thank all the speakers for their contributions in relation to the Gene Technology (Adoption of Commonwealth Amendments) Amendment Bill. I thank people for making a contribution on what could be seen by some, certainly not by me, as a dry piece of legislation that may be slightly technical in nature but is obviously important.

There is a whole variety of regulation functions that we have across the commonwealth. It is a federated model where we have a gene technology ministerial council meeting that meets. As the Minister for Health and Wellbeing, I represent South Australia on that ministerial council meeting.

From time to time, there will of course be changes that need to be made in relation to how the national scheme operates. This is something where the previous government and the previous minister put forward a piece of legislation that would allow automatic adoption of those amendments to happen here in South Australia. But of course, importantly, parliament would still retain the right to review and disallow the regulations, and only after consideration by the gene technology forum—of which, as I said, I am the representative—would those be made.

There are a number of other pieces of legislation where this already occurs in South Australia. There are some where it does not, and I think that in many ways a number of our laws are more conservative in that regard than what we see in other states. If you look at the controlled substances legislation or the health practitioner regulations, there are a number of matters where changes on the commonwealth basis are automatically applied in a number of other states around the commonwealth but still require some action from the South Australian government, whether that be regulation or gazettal, for that to occur here.

In relation to this, we would be saying that those changes would be made automatically. However, there would still be the ability for parliament, should there be a concern from either house, to disallow those regulations that were being made. I would like to thank members for their support for this bill and the people involved in SA Health for drafting it. I commend it to the house.

Bill read a second time.

Third Reading

The Hon. C.J. PICTON (Kaurna—Minister for Health and Wellbeing) (17:25): I move:

That this bill be now read a third time.

Bill read a third time and passed.

PARLIAMENTARY BUSINESS
MEMBERS
GET INVOLVED
ABOUT PARLIAMENT
VISIT
LEGISLATIVE COUNCIL
HOUSE OF ASSEMBLY
CONTACT